Compare CMCSA & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCSA | REGN |
|---|---|---|
| Founded | 1963 | 1988 |
| Country | | US |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.9B | 79.4B |
| IPO Year | N/A | 1995 |
| Metric | CMCSA | REGN |
|---|---|---|
| Price | $31.66 | $788.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 23 |
| Target Price | $35.01 | ★ $812.57 |
| AVG Volume (30 Days) | ★ 32.7M | 741.4K |
| Earning Date | 01-01-0001 | 04-16-2026 |
| Dividend Yield | ★ 4.18% | 0.47% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | N/A | ★ 41.48 |
| Revenue | N/A | ★ $5,872,227,000.00 |
| Revenue This Year | $1.82 | $11.69 |
| Revenue Next Year | N/A | $10.12 |
| P/E Ratio | ★ $5.86 | $19.04 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $25.75 | $476.49 |
| 52 Week High | $37.98 | $821.11 |
| Indicator | CMCSA | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 64.40 | 56.77 |
| Support Level | $31.12 | $783.62 |
| Resistance Level | $31.95 | $815.00 |
| Average True Range (ATR) | 0.88 | 24.67 |
| MACD | 0.11 | 3.10 |
| Stochastic Oscillator | 79.24 | 70.00 |
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to 65 million US homes and businesses, or nearly half of the country. The firm provides services to about half of the locations in this territory. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC network, the Peacock streaming platform, several local NBC affiliates, Universal Studios, and several theme parks. The firm plans to spin off most of its cable networks. Finally, Sky, acquired in 2018, is a large television provider in the UK and Italy.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).